Showing results (291-300 of 608) with videos related to

Sort By:
Pageof 61
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 27, 2022
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?Trishna Bharadia, Jo Vandercappellen, Tanuja Chitnis, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 27, 2022
Validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosisPedro Alves, Eric Green, Michelle Leavy, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 22, 2017
Serum retinol levels are associated with brain volume loss in patients with multiple sclerosisH Yokote, T Kamata, S Toru, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 12, 2017
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-upCarrie M Hersh, Thomas E Love, Anasua Bandyopadhyay, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 21, 2017
Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosisAlexander Y Lau, W K Ip, Cheryl Au, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 17, 2019
Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT studyLisanne J Balk, Danko Coric, Benjamin Knier, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 1, 2019
Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?Sarah L Minden, R Philip Kinkel, Helene T Machado, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 6, 2019
Initiating disease-modifying treatments in multiple sclerosis: Measuring the decision process using decisional conflict and decisional regret scalesD D Wilkie, A Solari, R Nicholas
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 26, 2019
Inflammatory activity and vitamin D levels in an MS population treated with rituximabJohan Linden, Gabriel Granåsen, Jonatan Salzer, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 24, 2021
Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up studyCecilie Jacobsen, Robert Zivadinov, Kjell-Morten Myhr, et al.
Pageof 61